Existing clinical studies have shown that tumour cells rely more than normal cells on a high level of SE-driven transcriptional regulation mediated by specific oncogenes, such as RUNX1 (encoding RUNX family transcription factor 1) in AML and MYCN in NB [6, 55]. The gene discussed is MYCN; the disease is acute myeloid leukemia.